Transplantation-related morbidity and mortality
| . | Fludarabine/melphalan/alemtuzumab (n = 78) . | Fludarabine/melphalan/MTX (n = 51) . | P . |
|---|---|---|---|
| Days to reach | |||
| More than 500 granulocytes | 12.88 (2.84) | 14.79 (2.14) | < .001 |
| More than 1 000 granulocytes | 13.7 (3.89) | 17.68 (3.09) | < .001 |
| More than 20 000 platelets | 14.49 (6.49) | 11.25 (5.34) | .009 |
| More than 50 000 platelets | 21.73 (14.1) | 14.14 (5.38) | .001 |
| Acute GVHD | Yes vs no .001 | ||
| No | 64 (82.1%) | 28 (54.9%) | 0-I vs II-IV |
| Grade I | 9 (11.5%) | 1 (2%) | < .001 |
| Grade II | 5 (6.4%) | 15 (29.4%) | 0-II vs III-IV |
| Grade III-IV | 2 (2.6%) | 7 (13.7%) | .015 |
| Overall acute GVHD (before + after DLI) | Yes vs no .006 | ||
| No | 60 (76.9%) | 28 (54.9%) | 0-I vs II-IV |
| Grade I | 10 (12.8%) | 1 (2%) | < .001 |
| Grade II | 3 (3.8%) | 15 (29.4%) | 0-II vs III-IV |
| Grade III-IV | 4 (5.1%) | 7 (13.7%) | .092 |
| Chronic GVHD | |||
| Limited | 1 | 9 | < .001 |
| Extensive | 1 | 13 | |
| CMV reactivation | 27 (46.6%) | 10 (22.7%) | .018 |
| CMV+ patient or donor | 26 (86.7%) | 7 (25%) | < .001 |
| CMV− patient and donor | 0 | 0 | |
| TRM | 8 (10.3%) | 10 (20%) | .12 |
| . | Fludarabine/melphalan/alemtuzumab (n = 78) . | Fludarabine/melphalan/MTX (n = 51) . | P . |
|---|---|---|---|
| Days to reach | |||
| More than 500 granulocytes | 12.88 (2.84) | 14.79 (2.14) | < .001 |
| More than 1 000 granulocytes | 13.7 (3.89) | 17.68 (3.09) | < .001 |
| More than 20 000 platelets | 14.49 (6.49) | 11.25 (5.34) | .009 |
| More than 50 000 platelets | 21.73 (14.1) | 14.14 (5.38) | .001 |
| Acute GVHD | Yes vs no .001 | ||
| No | 64 (82.1%) | 28 (54.9%) | 0-I vs II-IV |
| Grade I | 9 (11.5%) | 1 (2%) | < .001 |
| Grade II | 5 (6.4%) | 15 (29.4%) | 0-II vs III-IV |
| Grade III-IV | 2 (2.6%) | 7 (13.7%) | .015 |
| Overall acute GVHD (before + after DLI) | Yes vs no .006 | ||
| No | 60 (76.9%) | 28 (54.9%) | 0-I vs II-IV |
| Grade I | 10 (12.8%) | 1 (2%) | < .001 |
| Grade II | 3 (3.8%) | 15 (29.4%) | 0-II vs III-IV |
| Grade III-IV | 4 (5.1%) | 7 (13.7%) | .092 |
| Chronic GVHD | |||
| Limited | 1 | 9 | < .001 |
| Extensive | 1 | 13 | |
| CMV reactivation | 27 (46.6%) | 10 (22.7%) | .018 |
| CMV+ patient or donor | 26 (86.7%) | 7 (25%) | < .001 |
| CMV− patient and donor | 0 | 0 | |
| TRM | 8 (10.3%) | 10 (20%) | .12 |